Objective This clinical trial aimed to compare the efficacy of lorazepam and oxazepam in treatment of patients with alcoholic liver diseases (ALD) and alcohol withdrawal syndrome (AWS). Methods A total of 127 patients with ALD and AWS were enrolled in our hospital between November 2017 and November 2020, and were randomly divided into control (n=63) and observation group (n=64), receiving lorazepam and oxazepam, respectively, for seven days. The scores of alcohol withdrawal syndrome scale (AWSS) and self-rating anxiety scale (SAS) score were evaluated. Serum hyaluronic acid (HA), laminin (LN), type III procollagen N-terminal peptide (PC-III) and type-IV collagen (IV-C) were detected by ELISA. Results At the end of 7 day treatment, the efficient rate in observation group was 96.9％, significantly higher than 81.0％ in the control (P<0.05); at presentation, the AWSS and SAS, serum alanine transaminase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT),total bilirubin (TBIL) and alkaline phosphatase (ALP) as well as HA, LN, PC-Ⅲ and IV-C levels were not significantly different between the two groups(P>0.05); after treatment, the AWSS and SAS in observation were (9.5±2.4) and (30.8±6.4), significantly different as compared to in the control; serum ALT, AST, GGT, TBIL and ALP levels were (30.5±8.1)U/L, (71.6±15.3)U/L, (466.1±22.7)U/L, (23.5±6.5)μmol/L and (82.3±12.4)U/L, all much lower than in the control; serum HA, PC-Ⅲ and IV-C levels were (116.8±18.3)μg/L,(123.1±12.3)μg /L and (80.2±11.6)μg /L, significantly lower than in the control. Conclusion The clinical efficacy of oxazepam is good in treatment of ALD patients with complicated AWS, which could improve clinical symptom and anxiety relieving.

Objective The aim of this study was to observe the efficacy of silibinin and polyene phosphatidylcholine combination therapy in patients with anti-tuberculosis drugs-induced liver injury (DILI). Methods 118 patients with pulmonary tuberculosis were encountered in our hospital between June 2018 and June 2021, and all received standardized anti-tuberculosis treatment by 2HRS( E) Z /4HR for six months. During the process, 63 patients were found having DILI, and were randomly divided into control (n=30) and observation (n=33) groups, receiving polyene phosphatidylcholine or silibinin capsule and polyene phosphatidylcholine combination therapy until the anti-tuberculosis regimen ended. Serum interleukin-2 (IL-2), IL-6, IL-1β and tumor necrosis factor-α (TNF-α) levels were detected by ELISA, serum superoxide dismutase (SOD) was detected by radioimmunoassay and serum reduced glutathione (GSH) and malondialdehyde (MDA) levels were assayed by biochemical colorimetry. Results After treatment, serum ALT, AST and GGT levels in the observation group were (32.8±6.1)U/L, (41.2±8.3)U/L and (36.1±6.5)U/L, all significantly lower than [(48.6±8.4)U/L, (53.8±9.2)U/L and (53.8±9.6)U/L, respectively, P<0.05] in the control; serum IL-6, IL-1β and TNF-α levels in the observation were (6.3±1.0)ng/L, (11.0±2.3)μg/L and (6.8±1.5)ng/L, all much lower than [(9.5±1.2)ng/L, (19.2±3.6)μg/L and (9.9±1.3)ng/L, respectively, P<0.05] in the control, while there was no significant difference respect to serum IL-2 levels in the two groups (P>0.05); serum SOD and GSH levels in the observation group were (597.3±71.6)U/L and(7.6±1.5)μmol/L, both significantly higher than [(542.8±68.2)U/L and (6.2±1.3)μmol/L, P<0.05], while serum MDA level was (4.0±0.7)nmol/L, much lower than [(5.8±0.9)nmol/L, P<0.05] in the control. Conclusion The administration of silibinin capsule and polyene phosphatidylcholine combination in treatment of patients with pulmonary tuberculosis during anti-tuberculosis therapy could protect the liver function test normal, and maintain the accomplishment of anti-tuberculosis treatment, which might be related to the relieving inflammation and oxidative stress response.

Objective The purpose of this study was to observe the application of entecavir and magnesium isoglycyrrhizinate combination in the treatment of patients with chronic hepatitis B (CHB). Methods A total of 98 patients with CHB were enrolled in our hospital between January 2019 and February 2020, and were randomly divided into control (n=49) and observation group (n=49), receiving entecavir or entecavir and magnesium isoglycyrrhizinate combination therapy for 48 weeks. Serum hyaluronan (HA), laminin (LN), type-IV collagen (CIV) and type-III procollagen (PIIIP) levels were detected by radioimmunoassay. Serum interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 10 (IL-10) and tumor necrosis factor α (TNF-α) levels were detected by ELISA. The peripheral blood T lymphocyte subsets were detected by flow cytometry. Results At the end of 48 week observation, serum ALT normalization rate in the observation group was 87.8%, significantly higher than 71.4%(P＜0.05) in the control; serum ALT and AST levels in the combination group were (32.3±6.9)U/L and (38.3±4.7)U/L, both significantly lower than [(47.5±7.6)U/L and (52.9±5.1)U/L, respectively, P＜0.05] in the control; serum HA and PⅢP levels were (90.6±9.5)ng/mL and (141.6±32.6)ng/mL, both significantly lower than [(126.8±14.6)ng/mL and (168.2±29.9)ng/mL, respectively, P＜0.05] in the control; serum IL-4 and TNF-α levels were (48.8±7.9)ng/L and (11.3±1.9)ng/L, significantly lower than [(62.6±8.8)ng/L and (18.5±1.7)ng/L, respectively, P＜0.05], while serum IL-10 level was (19.2±2.5)ng/L, significantly higher than [(12.7±3.4)ng/L, P＜0.05] in the control; the percentage of peripheral blood CD4⁺ cells and the ratio of CD4⁺/CD8⁺ cells were (43.5±5.5)% and (1.6±0.2), both significantly higher than [(38.4±4.7)% and(1.4±0.4), respectively, P＜0.05] in the control group. Conclusion The application of entecavir and magnesium isoglycyrrhizinate combination in the treatment of patients with CHB could effectively improve liver function test normal, inhibit the process of liver fibrosis, which might be related to the inhibition of inflammatory reaction and modulation of immune system.

Objective The purpose of this clinical trial was to investigate the auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B (CHB). Methods 60 patients with CHB were enrolled in our hospital between January 2019 and January 2021, and were randomly divided into control and observation groups, with 30 cases in each. The patients in the control group received entecavir, and those in the observation were treated with entecavir and a herbal compound, Ganshuang granule, for 48 weeks. The AST to platelet ratio index (APRI), fibrosis 4 score (FIB-4) were obtained, and the liver stiffness measurement (LSM) was determined by FibroTouch scan. Serum interleukin-6(IL-6), transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF) and C-reactive protein (CRP) levels were assayed by ELISA. Results At the end of 48 week treatment, serum ALT and AST levels in the observation group were significantly lower than in the control group (P<0.05); serum HBV DNA loss in the two groups were both 100.0%, and serum HBeAg negative rates were both 0.0% (P>0.05); the APRI, FIB-4 and LSM in the observation group were (1.02±0.23), (4.38±0.77) and (7.73±1.53), all significantly lower than [(1.30±0.33), (5.26±0.85) and (9.68±2.02), respectively, P<0.05] in the control; serum IL-6, TGF-β, PDGF and CRP levels in the observation were much lower than in the control (P<0.05). Conclusion The auxiliary treatment of Ganshuang granule at base of entecavir antiviral therapy could significantly improve biochemical response in patients with CHB, which might be related to the anti-fibrotic effect and inhibition of body inflammatory reaction of the herbal compound.

Objective The aim of this study was to investigate the short-term efficacy of dapagliflozin and liraglutide combination in treatment of patients with non-alcoholic fatty liver disease (NAFLD) and diabetes mellitus type 2(T2MD). Methods 60 patients with NAFLD and T2MD were admitted to our hospital between September 2017 and October 2020, and were randomly divided into control and observation group, with 30 cases in each group. All the patients were supervised for routine lifestyle intervention and oral metformin administration for blood glucose control. In addition, the patients in the control group were treated with liraglutide intravenouly, and those in the observation group were treated with dapagliflozin and liraglutide combination. The regimen lasted for 3 months. The fasting plasma glucose (FPG), 2 hour-postprandial plasma glucose (2h PG) and glycated hemoglobin (HbA1c) as well as serum triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL－C) and high density lipoprotein cholesterol (HDL－C) levels were routinely obtained. Serum fasting insulin(Fins) and 2 h Ins levels were assayed, and the HOMA-IR was calculated. The controlled attenuation parameter (CAP) of livers was detected by FibroTouch. Results At the end of 3 month observation, the FPG, 2hPG and HbA1 levels in the observation group were(5.8±0.7)mmol/L, (6.9±0.8)mmol/L and (6.3±0.9)%, all significantly lower than [(6.6±0.6)mmol/L,(7.7±0.7)mmol/L and (7.2±1.0)%, respectively, P＜0.05] in the control group; serum Fins, 2hIns and HOMA-IR levels were (9.8±1.2)mIU/L, (20.2±1.7)mIU/L and (2.6±0.4)%, significantly lower than [(11.9±1.1)mmol/L, (24.8±1.6) mmol/L and (3.2±0.5)%, respectively, P＜0.05] in the control; serum TG level was (2.6±0.4) mmol/L, significantly lower than [(3.0±0.3)mmol/L, P＜0.05], while serum HDL-C level was (1.6±0.2) mmol/L, significantly higher than [(1.2±0.3)mmol/L, P＜0.05] in the control; the CAP was (249.2±7.5)dB/m, also significantly lower than [(264.7±8.6)dB/m, P＜0.05] in the control; serum AST level was (39.9±3.8)U/L, significantly lower than [(44.9±4.2)U/L, P＜0.05] in the control. Conclusion The application of dapagliflozin and liraglutide combination is efficacious in the treatment of patients with NAFLD and T2MD, which could effectively reduce blood glucose and lipid levels, improve liver function tests back to normal, with the ability of alleviation of insulin resistance.

Objective The aim of this study was to summarize the clinical features of patients with benign recurrent intrahepatic cholestasis (BRIC). Methods The clinical manifestations, laboratory tests, imaging, pathological examinations, and genetic analysis in three patients with BRIC in Zhongshan Hospital, Fudan University, were retrospectively reviewed. Results The three patients were all male and their initial onset ages were below 20 year old; the common symptoms of the patients were jaundice and pruritus, and two of them also experienced abdominal distension, irregular defecation, and appetite loss; serum total bilirubin, direct bilirubin, ALP and TBA levels increased significantly, while serum GGT, ALT and AST levels stayed normal or increased slightly during the disease attack duration; no abnormal intrahepatic and extrahepatic bile ducts were found in magnetic resonance cholangiopancreatography (MRCP) examination, but obvious cholestasis of hepatocytes and capillary bile duct embolism were observed in liver histopathology; the ATP8B1 gene mutation sites with functional prediction of "potentially harmful" or "likely pathogenic" in pathogenic classification were all detected in three patients; all patients were excluded from other known causes of cholestasis, and the disease was recurrent, but with self-limiting. Conclusion The BRIC is rarely reported and its pathogenesis remains unclear currently. The clinical diagnosis might be made based on clinical manifestations, ancillary tests, and pathological findings after excluding other common causes of liver damage. For patients with high suspicion of BRIC, the genetic tests should be performed as early as possible to clarify the diagnosis and guide the management.

The Chinese Society of Hepatology of the Chinese Medical Association invited relevantexperts to revise and update the Guideline of Prevention and Treatment of Nonalcoholic Fatty Liver Disease(2018Version) and renamed it as (Version 2024) Guideline for the Prevention and Treatment of MetabolicDysfunction-associated (non-alcoholic) Fatty Liver Disease. Herein, the guiding recommendations on clinicalissues such as screening and monitoring, diagnosis and evaluation, treatment and follow-up of metabolicdysfunction-associated fatty liver disease are put forward.

Objective The aim of this study was to explore the clinical efficacy of programmed cell death protein-1 (PD-1) inhibitor and lenvatinib in the treatment of elderly patients with advanced primary liver(PLC). Methods 56 patients with advanced PLC were admitted to our hospital between February, 2017 and February, 2020, and were divided into control (n=28) and observation group (n=28), receiving lenvatinib or PD-1 inhibitor, tirelizhu, and lenvatinib combination therapy. The peripheral blood lymphocyte subsets, CD4⁺ cell surface PD-1 and cytotoxic T-lymphocyte antigen 4 (CTLA-4) were detected by FCA. Serum acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels were detected by ELISA. Results At the end of three month treatment, there were no significant differences as respect to the objective remission rate (42.9% vs. 25.0%) and local control rate(78.6% vs. 64.3%, P>0.05); the percentages of CD3⁺, CD4⁺ and CD8⁺ cells in the combination treatment group were much higher than, while the CD4⁺/CD8⁺ cell ratio, as well as the cell PD-1 and CTLA-4 expression were much lower than in the control (P<0.05); serum aFGF, bFGF and VEGF levels in the observation group were (4.1±0.8)pg/L, (5.1±1.0)pg/L and (13.5±2.7)ng/ml, all significantly lower than [(5.3±0.9)pg/L, (6.1±0.8)pg/L and (18.6±3.1)ng/ml, respectively, P<0.05] in the control; at the end of two-year follow-up, there was no significant difference respect to the progression free survival (10.7% vs. 21.4%, P>0.05) between the two groups, while the overall survival in the observation group was 60.7%, much higher than 25.0% (P<0.05) in the control. Conclusion The strategy of PD-1 inhibitor and lenvatinib combination in the treatment of elderly patients with advanced PLC could improve immune functions and prognosis, which needs further investigation.

Objective To investigate the changes of serum carbohydrate antigen（CA）125,CA199, alpha-fetoprotein （AFP） and carcinoembryonic antigen （CEA） in patients with live cirrhosis and primary liver cancer（PLC）. Methods Serum levels of CA125,CA199,AFP and CEA in 440 individuals were detected by ELISA,including 223 patients with liver cirrhosis,97 patients with PLC and 120 healthy persons. Results The levels of CA125 in patients with liver cirrhosis and PLC were （261.64±32.47） U/ml and （265.80±30.44 ） U/ml, CA199 were （25.73±3.39） U/ml and （30.54±3.29） U/ml,CEA were （4.03±0.36） ng/ml and （3.87±0.21） ng/ml,much higher than those[（21.25±7.66） U/ml,（18.57±8.11） U/ml and （3.08±1.05） ng/ml,P<0.05] in healthy persons;serum AFP levels in patients with PLC were（20000.00±453.07） ng/ml,much higher than[（7.52±2.01） ng/ml,P<0.05] in patients with liver cirrhosis;The levels of CA125（474.52±59.80） U/ml],CA199 [（27.80±5.94） U/ml] and CEA [（5.80±0.63） ng/ml] in patients with liver cirrhosis of class C were significantly higher than those of class A [（55.65±8.82） U/ml,（18.81±0.46） U/ml and （3.20±0.10） ng/ml,respectively,P<0.05];The levels of CA125[（385.16±36.09） U/ml],CA199[（26.55±2.87） U/ml],AFP[（13.63±1.82） ng/ml] and CEA [（4.85±0.39） ng/ml] in patients with cirrhotic ascites were higher than those without ascites[（62.75±15.45） U/ml,（19.58±0.75） U/ml,（9.39±1.26） ng/ml and （3.54±0.16） ng/ml,P<0.05];The levels of CA125 [（318.48±48.80）U/ml] and CA199 [（26.63±3.22）U/ml] in patients with alcoholic liver cirrhosis were higher than those in patients with viral cirrhosis [（215.77±26.26）U/ml and（19.06±0.64）U/ml,P<0.05] or in patients with primary biliary cirrhosis [（129.73±28.55）U/ml and（18.00±0.00） U/ml,P<0.05];The level of AFP [（56.41±26.75）ng/ml] in patients with viral cirrhosis was higher than[（5.44±0.30） ng/ml or（7.35±1.47） ng/ml,respectively,P<0.05],while the CEA level[（3.53±0.17） ng/ml] was lower than [（5.19±0.35） ng/ml or（5.73±0.98） ng/ml,P<0.05] in patients with alcoholic liver cirrhosis or primary biliary cirrhosis. Conclusion The serum levels of CA125,CA199,AFP and CEA in patients with liver cirrhosis and PLC were different. The serum levels of CA125,CA199,AFP and CEA in patients with liver cirrhosis were associated with Child-Pugh scores,ascites and etiology.

Objective The aim of this study was to investigate the early efficacy of tenofovir amibufenamide (TMF) in the treatment of naïve patients with chronic hepatitis B (CHB). Methods A total of 90 naïve patients with CHB were recruited in the First Affiliated Hospital, China University of Science and Technology between January 2020 and March 2022, and were divided into observation (n=50) and control group (n=40), receiving TMF or tenofovir disoproxil fumarate (TDF) treatment for 48 weeks. Serum alanine transaminase (ALT), HBV DNA loads, HBeAg and HBsAg levels were detected routinely. Results At 12, 24, 36 and 48 weeks of treatment, serum ALT levels in the observation group were 38.0(25.0,55.0)U/L, 31.5(23.8,35.0)U/L, 29.5(22.8,35.0) U/L and 26.0(21.8,34.0)U/L, all not significantly different compared to 38.5(25.0,60.0)U/L, 30.0(22.0,44.0)U/L, 31.0(22.8,44.5)U/L and 28.0(19.8,42.0)U/L (P>0. 05), serum HBV DNA loads were 0(0, 3)lgIU/ml, 0(0, 0.5)lgIU/ml, 0(0, 0)lgIU/ml and 0(0, 0)lgIU/ml, not significantly different compared to 2(0, 3)lgIU/ml, 0(0, 2)lgIU/ml, 0(0, 1.5)lgIU/ml and 0(0,0)lgIU/ml (P >0.05) in the control; serum HBV DNA loss were 58%, 76%, 78% and 88%, not significantly different compared to 45%, 65%, 75% and 85%(P >0.05) in the control; at 12, 24 and 36 week treatment, serum ALT normalization rates in the observation group were 56%, 80% and 92%, all not significantly different compared to 55%, 70% and 65%(P >0.05) , while at the end of treatment 48 week, serum ALT normalization rate in the observation group was 100.0%, much higher than 72.5%(P＜0.01) in the control; during the period of antiviral regimen, there was no obvious untoward effects in the two groups. Conclusion The antiviral performance of TMF in the treatment of naïve patients with CHB is as efficacious as of TDF, while the long-term efficacy and its impact on renal functions needs further clinical investigation.

Objective The aim of this study was to summarize the imaging features of multi-slice spiral CT (MSCT) in patients with gallbladder adenomyosis and in patients with gallbladder carcinoma. Methods 113 patients with gallbladder adenomyosis and 78 with gallbladder carcinoma were enrolled in our hospital between September 2015 and September 2020, and all patients underwent MSCT and ultrasonography. The histophthological examination was performed after surgery. Results The consistency of diagnosis by MSCT based on postoperative histopathological examination (Kappa=0.749) was stronger than that by ultrasonography (Kappa=0.577); the accuracy rate by MSCT scan in the diagnosis of patients with gallbladder adenomyosis was higher than that by ultrasonography(88.0% vs. 79.6%, P<0.05); the diagnosis of special, local gallbladder adenomyosis, by MSCT was also higher than that by ultrasonography (97.1% vs. 82.9%, P<0.05); the CT scan showed that the percentages of smooth gallbladder walls, RAS sinus display and clear boundary between liver and gallbladder in patients with gallbladder adenomyosis were 36.3%, 36.3% and 69.0%, all significantly higher than 9.0%, 6.4% and 38.5% in patients with gallbladder carcinoma (P<0.05). Conclusion The diagnostic accuracy of patients with gallbladder adenomyosis by MSCT is relatively high, and its imaging feature might help discriminate gallbladder adenomyosis from cancer.

Objective Bile acid(BA) is synthesized in the liver and is the major component of bile. BAs accumulates in serum and liver when BAs secretion is impaired, which is followed by liver injury. The molecular mechanism of cholestasis has been extensively studied, however, it remains controversial. Recent studies showed that BAs might induce hepatocyte injury under pathological conditions, and the mechanism involved inflammatory response induced by stressed hepatocytes. In this article, we reviewed recent advances in the pathogenesis of liver injury induced by BAs and we focused on how BAs induce the activation of inflammatory cytokines that further induce the aggregation of immune cells. Based on these pathogenesis, we tentatively point out a number of novel treatments for cholestatic liver damage.

Objective The aim of this study was to summarize the clinical features of patients with Dengue fever (DF), especially in those with liver injuries. Methods 70 patients with DF were encountered in our hospital from January to December 2020, and were carefully managed by supporting treatment. The patients with liver injuries were dealt with liver-protecting medicines. The clinical feature, including blood and biochemical parameters was collected. Results Out of 70 patients with DF, the main symptoms included fever, arthralgia, rash, abdominal pain, diarrhea, respiratory and urinary tract infections, and the leukopenia in 34 cases, thrombocytopenia in 35 cases and abnormal liver function tests in 33 cases; the hospital stay in 33 patients with liver injuries was (7.1±2.2) d, significantly longer than [(5.8±2.0), P<0.05] in 37 patients without liver injuries; all the 70 patients recovered; there was no significant difference as respect to peripheral white blood cell counts between patients with and without liver injuries (P>0.05), while the platelet counts in patients with liver injuries was (105.0±48.6)×10⁹/L, significantly lower than [(156.2±88.7)×10⁹/L, P<0.05] in those without liver injuries; serum ALT, AST, GGT, C-reactive protein and MB isoenzyme of creatine kinase levels slightly increased in patients with liver injuries and the outcomes was good. Conclusions The patients with Dengue fever could have complicated slight liver injuries, and the liver-protecting management could improve the recovery.

Objective The aim of this study was to investigate the clinical predicting value of serum ascites albumin gradient (SAAG) on esophageal variceal bleeding (EVB) risk in patients with decompensated hepatitis B cirrhosis. Methods 84 patients with decompensated hepatitis B cirrhosis were admitted to our hospital between April 2017 and October 2019, and the SAAG and modified SAAG werecalculated. The Logistic multivariate analysis was used to analyze the independent impacting factors on EVB in patients with decompensatedhepatitis B cirrhosis. The receiver operating characteristic curve (ROC) was drawn and the area under the ROC (AUROC) was calculated to predict the EVB risk. Results 18 out of our series had, and 66 patients had not EVB during six-month followed-up period; the percentage of male cases older than 65 yr in patients with EBV was 72.2%,greatly older than in patients without EBV (43.9%,P<0.05); serum albumin level in patients with EVB was (35.8±2.7)g/L, significantly lower than , blood platelet count was (52.3±10.7)×10⁹/L, significantly lower than , the APTT was (45.8±5.9)s, significantly longer than ,the SAAG was (18.7±5.1), significantly higher than , and the modified SAAG was (9.2±2.4), significantly higher than in patients without EVB; the spleen thickness was (5.2±1.3)cm, significantly higher than , and the portal vein blood flow velocity was (15.2±2.9) cm/s, significantly slower than in patients without EVB; the multivariate Logistic analysis showed that serum albumin level (OR=0.435, 95%CI=0.287-0.659), ascites albumin level(OR=1.845, 95%CI=1.063-3.202), the APTT(OR=1.469,95%CI=1.272-1.697), the MELD score (OR=3.285, 95%CI=1.697-6.359) and the modified SAAG(OR=2.917, 95%CI=1.337-6.364) were the independent impacting factors for EVB in patients with decompensated hepatitis B cirrhosis(P<0.05); the AUCs of modified SAAG and MELD score for predicting EVB were 0.827 and 0.791, respectively, and theirsensitivities were 0.889 and 0.787, and the specificities were 0.636 and 0.612, respectively. Conclusion The application of SAAG is helpful to predict the risk of EVB in patients with decompensated hepatitis B cirrhosis, and worth further clinical investigation.

Objective The aim of this study was to investigate the short-term efficacy of silybin meglumine and Danning tablet, a herbal medicine, combination in treatment of patients with alcoholic hepatitis (AH). Methods 146 consecutive patients with AH were recruited in our hospital between March 2017 and June 2019, and were randomly divided into control group (n=73) and observation group (n=73). The patients in the control group were given Danning tablets, and those in the observation group were treated with silybin meglumine and Danning combination for 3 months. Serum superoxide dismutase (SOD), alondialdehyde (MDA) and free fatty acid (FFA) were detected. Results Serum total cholesterol (TC) level in the combination group was (4.9±0.7)mmol/L, significantly lower than 【(5.5±1.2)mmol/L, P<0.05】, and high density lipoprotein cholesterol (HDL-C) was (1.3±0.9)mmol/L, much higher than 【(1.0±0.5)mmol/L, P<0.05】 in the control, and serum triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) levels in the two groups were not significantly different 【(1.7±0.3)mmol/L vs. (1.7±0.7)mmol/L and (3.2±0.4)mmol/L vs. (3.4±0.7)mmol/L, respectively, P>0.05】; serum alanine aminotransferase level was (35.9±7.7)U/L, serum aspartate aminotransferase level was (39.5±6.3)U/L, serum glutamyl transpeptidase level was (123.8±6.6)U/L, and serum alkaline phosphatase level was (57.3±12.5)U/L, all significantly lower than those in the control [(63.5±9.2)U/L,(65.5±7.8)U/L,(145.7±7.2)U/L and (78.4±13.1)U/L, respectively, P<0.05】; serum SOD level was (132.9±19.3)nmol/L, much higher than 【(105.5±12.6)nmol/L, P<0.05】, serum MDA level was (9.5±2.3)nmol/L, significantly lower than 【(14.4±3.6)nmol/L, P<0.05】, and serum FFA level was (24.3±3.1)nmol/L, much lower than 【(30.2±3.3)nmol/L, P<0.05】 in the control. Conclusion The administration of silybin meglumine and a herbal medicine combination in treatment of patients with AH might in short-term ameliorate blood lipid metabolism, inhibit oxidative stress and improve liver functions, which needs further multi-central investigations.

Objective The aim of this study was to investigate the efficacy of of combination of tenofovir and Anluo Huaxian pill,a herbal medicine,in the treatment of patients with HBeAg-negative chronic hepatitis B （CHB）. Methods A total of 68 patients with HBeAg-negative CHB were recruited in our hospital bwtween March 2015 and May 2017,and were divided randomly into two groups,with 34 patients in each. The patients in the control group were treated with tenofovir orally and those in the observation were treated with combination of tenofovir and Anluo Huaxian pill for 48 weeks. Serum interleukin（IL）-6,IL-2,and tumor necrosis factor-α（TNF-α） by enzyme-linked immunosorbent assay,and serum type III procollagen（PC-III）,hyaluronic acid （HA）,laminin （LN） and type IV collagen （IV-C） were detected by radioimmunoassay. Results At the end of 48 w treatment,serum HA,LN,IV-C,and PC-III levels in the combination group were（94.5±31.5） ng/ml,（113.2±51.6） ng/ml, （72.4±20.3） g/L and （102.4±19.6） g/L,significantly lower than [（121.6±37.5） ng/ml,（132.5±53.8） ng/ml,（94.6 ±22.1） μg/L and（134.7±21.5） g/L,respectively,P<0.05] in the control;serum IL-2 level was （173.6±28.3） ng/L, significantly higher than [（145.7±26.4） ng/L,P<0.05], while serum IL- 6 and TNF-α levels were （94.5±16.2） pg/ml and（26.6±6.8） pg/ml,significantly lower than [（112.6±17.8） pg/ml and（35.7±8.3） pg/ml,respectively,P<0.05] in the control;serum HBV DNA loss were 91.2% and 88.2% in the two groups（P<0.05） and serum ALT normalization rates in the two groups were 94.1% and 94.1%. Conclusion The administration of tenofovir and Anluo Huaxian pills is effective in the treatment of patients with HBeAg-negative CHB, which might alleviate liver fibrosis and reduce intrahepatic inflammation.

Objective This study was designed to evaluate of reliability and validity of self-rating anxiety scale（SAS） and self-rating depression scale（SDS） in patients with liver cirrhosis. Methods A total of 138 patients with liver cirrhosis were enrolled in this study. The reliability and validity of the two scales was evaluated by Cronbach’s α co-efficient,intraclass correlation co-efficient （ICC）,Kaiser-Meyer-Olkin （KMO） score and Bartlett’s test of sphericity（BTS）. Results The prevalence of anxiety and depression in this series were 38.2% and 63.1%,respectively;SAS scale’ Cronbach's α coefficient was 0.777 and SDS scale’ was 0.782, indicating better homogeneity reliability; Twenty items of SAS and SDS scales were analyzed by exploratory factors to construct validity and four main factors were extracted from the SAS scale that showed the variances ratio were 15.4%,14.9%,10.6% and 10.2%,respectively,and four factors accounted for 51.1% of the total variance of accumulated explanation;Five main factors were extracted from SDS scales that showed the variance ratio were 14.0%,12.6%,11.9%,10.3% and 8.4%,respectively,with 57.4% of the total variance;The re-measurement analysis of SAS and SDS scale’s items found that the two measurements were highly correlated with each other （P<0.001）. Conclusion SAS and SDS scales have a better reliability and validity in the investigation of psychological and mental impairment in patients with liver cirrhosis.

Objective The aim of this study was to compare the antiviral response to pegylated interferon-α (PEG-IFNα-2a) or PEG-IFNα-2b in patients with chronic hepatitis B (CHB). Methods 74 patients with CHB were enrolled in our hospital between July 2016 and May 2018, and were randomly divided into group A (n=37) and group B (n=37). The patients in group A were treated with PEG-IFNα-2a, and those in group B were treated with PEG-IFNα-2b. The antiviral therapy lasted for 48 w, and all patients were followed-up for 24 weeks. Results At the end of 12 w, 24 w and 48 w treatment and 24 w followed-up, serum alanine aminotransaminase (ALT) normalization rates in goup A were 29.7%, 35.1%, 83.8% and 75.7%, all not significantly different as compared to 27.0%, 29.7%, 86.5% and 78.4%, respectively, (P>0.05) in group B; serum HBV DNA loss were 59.5%, 73.0%, 78.4% and 75.7%, all not significantly different as compared to 45.9%, 51.4%, 81.1% and 75.7%, respectively, (P>0.05) in group B; serum HBeAg negative rates were 33.3%, 36.7%, 36.7% and 40.5%, all not significantly different as compared to 29.2%, 29.2%, 33.3% and 35.1%, respectively, (P>0.05) in group B; during the treatment, the incidences of flu-like symptoms and abnormal thyroid functions in the two groups were the same, and the incidences of thrombocytopenia and granulocytopenia in group A were 40.0% and 76.6%, both notsignificantly different as compared to 37.8% and 75.7% in group B (P>0.05).Conclusion At present, both PEG-IFNα-2a and PEG-IFNα-2b could be selected for the treatment of patients with CHB, and the surveillance of untoward effects is pivotally important for the regimen going and the achievement of antiviral therapy.

Objective Esophageal and gastric varices bleeding (EGVB) is a common complications of liver cirrhosis, with a high mortality rate. Therefore, the prevention and treatment of EGVB is very important for patients with liver cirrhosis. Internal medicine, endoscopic management, interventional and surgical operation are all important approaches for the prevention and treatment of EGVB, which greatly improves the survival rate of cirrhotic patients. In this paper, we reviewed the current progress of primary prevention, emergent hemostasis and secondary prevention of patients with different types of esophageal and gastric varices.

Objective The aim of this experiment was to explore the effect and underlying mechanism of curcumin on oleic acid-induced steatosis of HepG2 cells in vitro. Methods HepG2 cells were treated with or without 1 mmol/L oleic acid (OA) to establish nonalcoholic fatty liver disease (NAFLD) cell model. The HepG2 cells were divided into four groups, e.g. control (con), steatosis model (OA) , curcumin control and curcumin-intervened groups. Bodipy493/503 staining was used to detect the distribution of lipid droplets in the HepG2 cells. The ultrastructure of mitochondria was examined by transmission electron microscopy. Reactive oxygen species (ROS) levels were detected by DCFH-DA. The TNF-α and IL-6 levels in the supernatants were measured by a commercial kit. The apoptosis was determined by Hoechst 33258 staining. Western blott was applied to determine the expression of Bcl-2, Bax, mCytc, NF-κB, and Caspase-3/9 proteins. Results Compared with in the control cells, the cells treated with OA showed significantly increased lipid droplets accumulation, while the cells treated with curcumin showed reduced lipid droplets accumulation; the mitochondrial damage including mitochondrial swelling and vesiculation in OA group was more obvious than that in control group, while the mitochondrial damage treated by curcumin was significantly improved; the TNF-α and IL-6 levels in OA group were much higher than that in the control group , while they decreased greatly in curcumin-inervened group ; the ROS levels was (52.24±5.11)% in OA group, significantly higher than (6.71±2.31)% in the control group, while it decreased to (37.44±7.21)% in curcumin-treated group (P<0.05); the apoptosis rate in OA group was (12.12±0.72)%, significantly higher than (2.04±0.57)% in the control group, while it decreased significantly in curcumin-treated group ; the expressions of Bax, NF-κB and cleaved-Caspase-3/9 intensified, and Bcl-2 and mCytc decreased greatly in OA group as compare to those in the control, while the expressions of Bax, NF-κB and Caspase-3/9 decreased, and Cytc and Bcl-2 increased (P<0.05) in curcumin-intervened group. Conclusion Curcumin effectively prevent oleic acid-induced steatosis in HepG2 cells, which might be related to the alleviation of inflammatory reaction, oxidative stress and inhibition of apoptosis.

Objective The aim of this study was to summarize the conventional and contrast-enhanced ultrasonography (CEUS)manifestations of intrahepatic cholangiocarcinoma (ICC).Methods 52 patients with ICC were recruited in our hospital, and all underwent conventional and CEUS check-up.Results The gray-scale ultrasonography showed than the tumors presented with uniform hypoechoic in 23 cases (44.2%, uneven hypoechoic in 22 cases (42.3%), slightly hyperechoic and hyperechoic in 7(13.5%); the color Doppler flow imaging showed that the blood supply of lesions was in grade 0 in 11 cases (21.2%), in grade 1 in 9 cases (17.3%), in grade 2 in 28 cases (53.8%), and in grade 3 in 4 cases(7.7%); out of 51 eligible cases of ICC, the CEUS demonstrated that the enhancement performance in arterial phase was in typeⅠ, e.g. rapid overall uniform enhancement, in 10 cases (19.6%), and in type Ⅱ, e.g. rapid uneven enhancement, in 41 cases (80.4%), out of which, in subtype Ⅱa, the overall uneven enhancement, in 19 cases (37.3%), in subtype Ⅱb, the dendritic enhancement, in 9 (17.6%), in subtype Ⅱc, thick-walled irregular ring-like enhancement, in 6 (11.8%), and in subtype Ⅱd, ring-like and dendritic enhancement, in 7 (13.7%).Conclusion ICCs have some CEUS characteristic features, which might help for the early diagnosis.

Objective The aim of this study was to investigate the efficacy and safety of glecaprevir/pibrentasvir therapy in the treatment of patients with chronic hepatitis C (CHC) and genotype 1b infection. Methods A total of 138 patients with CHC and genotype 1b infection were admitted to the our hospital between July 2019 and August 2020, and were randomly divided into DAA-treated group, receiving glecaprevir/pibrentasvir treatment in 69 cases, and PR-treated group, receiving pegylated interferon alpha-2b and ribavirin combination treatment in another 69 cases. The regimen lasted for 12 weeks in both groups. The biochemical, hematology and virologic parameters were routinely detected. Results At the end of the treatment, serum aspartate aminotransferase and alanine aminotransferase levels in DAA-treated patients were (35.2±6.2)U/L and (30.7±5.4)U/L, both significantly lower than [(48.4±6.9)U/L and (45.4±6.1)U/L, respectively, P＜0.05] in PR-treated patients; the rapid virologic response, virologic response at end of treatment and sustained virologic response in DAA-treated patients were 78.3%, 95.7% and 95.7%, all significantly higher than 65.2%, 76.8% and 76.8%(P＜0.05) in PR-treated patients; during the treatment, the white blood cell counts and platelet counts in PR-treated patients were (3.4±1.4)×10⁹/L and (110.7±30.8)×10⁹/L, both significantly lower than [(6.3±1.3)×10⁹/L and (208.3±30.2)×10⁹/L, P<0.05] in DAA-treated patients; the incidence of untoward effects in patients receiving DAA treatment was 5.8%, very significantly lower than 84.1%(P<0.001) in patients receiving PR treatment. Conclusion The administration of glecaprevir/pibrentasvir in treating patients with genotype 1b-infected CHC is efficacious and safe with promising virologic response and low side effects, which warrants further clinical investigation.

Objective To systematically evaluate the efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease （NAFLD）. Methods We searched CNKI,VIP,WanFang Data,CBM,PubMed,The Cochrane Library,EMbase database and retrieved randomized controlled trials （RCT） on the observation of tauro ursodesoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with NAFLD since inception of database. Meta analysis was performed by using RevMan 5.3 software. Results A total of 682 NAFLD patients were included in 6 RCT studies,and 342 in the observation group were treated by tauro ursodesoxy cholic acid and polyene phosphatidyl choline,and 340 in the control group were treated by ursodeoxycholic acid and polyene phosphatidyl choline combination. The Results showed that the overall effective rate [RR=1.10,95%CI（1.03,1.18）,P=0.004],serum ALT reduction [MD=13.34,95%CI（12.20,14.48）,P<0.00001],AST reduction [MD=11.29,95%CI（5.85,16.72）,P<0.0001], GGT reduction [MD=22.54,95%CI（20.75,24.33）,P<0.00001],TG reduction[MD=0.48,95%CI（0.25,0.70）,P<0.0001],LDL-C reduction [MD=0.67,95%CI（0.51,0.83）,P<0.00001] and BMI reduction [MD=1.57,95%CI（1.29, 1.84）,P<0.00001] as well s HDL-C elevation [MD=0.23,95%CI（0.18,0.27）,P<0.00001] in the observation group in the treatment of patients with NAFLD were significantly superior to those in the control group; however,there was no significant difference between the two groups as respect to serum TC reduction [MD=0.30,95%CI（-0.03,0.64）,P=0.08] and the incidence of adverse reactions [RR=1.00,95%CI（0.41, 2.47）,P=1.00];the improvement of hepatic steatosis was also not significantly different between the two groups [RR=2.2,95%CI（0.97,4.98）,P=0.06]. Conclusion The efficacy of tauro ursodesoxy cholic acid combined with polyene phosphatidyl choline in the treatment of patients with NAFLD is good based on the domestic studies,which might be at a low level observations.

Objective The aim of this study was to investigate the therapeutic efficacy of bifidobacterium triple viable capsule and metformin in the treatment of patients with nonalcoholic fatty liver disease (NAFLD) and the changes of blood dark incubation of insulin receptor substrate 1(IRS1), IRS2 and glucose transporter -4(GLUT4) mRNA. Methods 70 patients with NAFLD were enrolled in our hospital between June 2018 and December 2019,and were randomly divided into control (n=35) and observation (n=35), receiving metformin hydrochloride or bifidobacterium triple viable capsules at base of metformin for three months. Peripheral blood IRS1, IRS2 and GLUT4mRNA were assayed by RT-PCR, and serum highly sensitive c-reactive protein (hs-CRP), interleukin -6 (IL-6) and IL-10 levels were also detected. Results At the end of three month treatment, the total fatty liver improvement rate in the observation group was 91.4%, which was significantly higher than that in the control group (68.6%, P<0.05); serum aspartate aminotransferase (AST) level in the observation group was (23.9±9.7) U/L, significantly lower than that in the control group , serum alanine aminotransferase (ALT) level was (45.5±12.3) U/L, much lower than that in the control group , and serum glutamyltranspeptidase (GGT) level was (66.9±11.9) U/L, significantly lower than that in the control group ; blood IRS1 mRNA was (2.1±0.2), which was much higher than that in the control group , peripheral blood IRS2 mRNA level was (2.3±0.4), which was significantly higher than that in the control group , and peripheral blood GLUT4 mRNA level was (2.5±0.4), which was also significantly higher than that in the control group ; serum hs-CRP level was (3.4±0.7) mg/L, significantly lower than that in the control group , serum interleukin-6(IL-6) level was (26.9±7.4)ng/L, significantly lower than that in the control group , and serum IL-10 level was (46.5±12.8)ng/L, significantly lower than that in the control group .Conclusion The combination of bifidobacterium triple viable capsule and metformin in treatment of patients with NAFLD could effectively improve the hepatic steatosis, which might be related to the elevation of peripheral blood IRS1, IRS2 and GLUT4 and inhibition of serum inflammatory factors.

Objective The aim of this experiment was to investigate the changes of lipid metabolism related genes in liver tissues of mice with nonalcoholic fatty liver diseases (NAFLD). Methods A NAFLD model was established in ten mice by feeding high-fat diet. The histopathological changes of the liver tissues were observed. Blood total cholesterol (TCH) and triglycerides (TG) levels were detected, and sterol regulatory element-binding proteins (SREBPs), acetyl coenzyme carboxylase (ACC) and fatty acid synthase (FAS) mRNA were detected by reverse transcription-polymerase chain reaction. Results The steatosis of liver cells was found in mice in NAFLD model group; blood TG and TCH levels in NAFLD model group were (0.63±0.13) mmol/L and (7.23±0.7) mmol/L, significantly higher than [(0.28± 0.06) mmol/L and (2.78±0.6) mmol/L, P<0.001] in ten mice in the control; at the end of 24 w experiment, hepatic FAS and SREBP-1 mRNA in NAFLD mice were (3.9±1.1) and (1.8±0.7), significantly higher than 【(1.0±0.3) and (1.0±0.4), FAS: t = 6.231, P<0.001; SREBP-1: t = 2.431, P =0.035】, while the ACC mRNA was (1.2±0.5), not significantly different as compared to 【(1.0±0.4), t = 0.765, P =0.462】 in the control. Conclusion The lipid metabolism related genes in liver tissue of mice with NAFLD are significantly up-regulated, which might play a pivotal role in the pathogenesis of NAFLD.

Objective To investigate the clinical efficacy of entecavir combined with live bifidobacterium and lactobacillus tablets in the treatment of B patients with decompensated liver cirrhosis. Methods 120 patients with hepatitis B induced decompensated liver cirrhosis in the Affiliated Hospital of the Southwest Medical University between Jan. 2015 and Aug. 2017 were randomly divided into control and observation groups. The patients in the control group were administrated entecavir and patients in the observation group were administrated entecavir and live bifidobacterium and lactobacillus tablets. The index of liver function,hepatic fibrosis,HBV DNA and the rate of spontaneous bacterial peritonitis were compared between the two groups. Results At the end of 12 weeks,serum levels of ALT and TBIL in combination treatment group were（70.2±6.2） U/L and（16.3±4.2） μmol/L,both significantly lower than （76.2±9.6） U/L and （26.3±5.2） μmol/L in the control group（P<0.05）;serum level of ALB in the treatment group was （32.5±4.2） g/L,significantly higher than（30.2±5.3）g/L in the control group（P<0.05）;at the end of 24 weeks,serum levels of ALT and TBIL in the treatment group were （12.2±3.2） U/L and（6.2±1.3） μmol/L,both significantly lower than （26.4±3.2）U/L and （11.2±3.2） μmol/L in the control group （P<0.05）;serum level of ALB in the treatment group was （37.8±2.3） g/L,significantly higher than （34.4±4.2） g/L in the control group （P<0.05）;serum LN and C- IV were （65.2±15.1）ng/ml and （85.5±8.5）ng/ml,much lower than【（75.3±10.3）ng/ml and （96.2±10.3）ng/ml in the control,respectively,P<0.05】;serum HBV DNA level was （1.0±0.1）lg copies/ml,no significantly different as compared to （1.7±0.3） lg copies/ml in the control （P>0.05）,and serum HBV DNA negativity rate was 100.0%,also no significantly different as compared to 90.0% in the control（P>0.05）;at the end of 12 w and 24 w,the SBP occurred in 5（8.3%） and in 2（3.3%）,significantly lower than in 10（16.7%） and in 8（13.3% in the control （P<0.05）;at the end of 24 w,3（5%） died in the combination group,much lower than 10（16.7%） in the control（P<0.05）. Conclusion Entecavir combined with live bifidobacterium and lactobacillus tablets has a good clinical efficacy in treatment of hepatitis B patients with decompensated liver cirrhosis,which is worth further investigation.

Objective The incidence rate of nonalcoholic fatty liver disease (NAFLD) is increasing. It might progress to the end-stage liver disease. However, there is still no specific treatment for this entity. Therefore, the establishment of representative animal models reflecting disease characteristics has become especially important. Although there are many different disease models, there is still a lack of NAFLD model which could cover the whole spectrum of this entity in human. In this paper, we reviewed the current progress on NAFLD model, focusing on animal model, 2D cell model, 3D liver model and their advantages and disadvantages.

Objective The aim of this study was to analyze the short-term efficacy of glicladine and insulin aspart 50 in the treatment of patients with non-alcoholic fatty liver diseases (NAFLD) and hepatogenic diabetes and to monitor the changes of homeostasis model assessment for insulin resistance (HOMA-IR) and index of β-cell function in homeostasis model assessment (HOMA-β).Methods 98 patients with NAFLD and hepatogenic diabetes were admitted to our hospital between January 2017 and December 2019 were randomly divided into control group (n=49) and observation group (n=49). The patients in the control group were treated with insulin aspart 50, while those in the observation group were treated with glicladine at the basis of insulin aspart 50. The regimen in both groups lasted for 12 weeks. The fasting blood glucose (FBG) , postprandial 2 hour blood glucose (2 h PG) and serum hemoglobin A1c (HbAlc) level were detected, and the HOMA-IR and HOMA-β were calculated. Serum liver function indexes were detected by automatic biochemical analyzer.Results At the end of 12 week treatment, the FPG level in observation group was (6.3±3.9) mmol/l, significantly lower than [ (7.8 ±1.2) mmol/l, P<0.05] in the control, the 2 h PG level was (8.4±2.6) mmol/l, significantly lower than [(11.5±2.8) mmol/l, P<0.05] in the control, and the HbAlc level was (7.1±1.6)%, significantly lower than [(8.3±1.9)%, P<0.05] in the control; the HOMA-IR in the observation group was (1.5±0.2) , significantly lower than [(2.4±03), P<0.05] in the control, while the HOMA-β was (42.9±8.7), significantly higher than [(33.5±7.2), P<0.05] in the control; serum alanine aminotransferase (ALT) level in the observation group was (53.9±13.7) U/L, significantly lower than [(72.2±19.6) U/L, P<0.05] in the control, and serum aspartate aminotransferase (AST) level was (22.1±6.3) U/L, significantly lower than [(46.4±6.9) U/L, P<0.05] in the control; Serum albumin, total bilirubin and glutamyl transpeptidase levels in the two groups were not significantly different before and after treatment (P>0.05).Conclusion The administration of glicladine and insulin aspart 50 in the treatment of patients with NAFLD and hepatogenic diabetes could significantly improve the blood sugar level recovery, which might related to the improvement of islet β cell functions and reduction of HOMA-IR.

Objective To investigate the interaction between Notch and LPS-LPS-Toll like receptor-4（TLR4）-NF-κB inflammatory signaling pathways in HepG2 cells stimulated with lipopolysaccharide （LPS）.Methods HepG2 cells were cultured with LPS and cell RNAs were extracted,and Notch signaling pathway receptors and their ligands mRNA were detected by quantitative reverse transcription polymerase chain reaction. Western blot analysis was used to detect Notch intracellular domain（NICD） and NF-κB protein expression levels after the γ-secreting enzyme inhibitor （DAPT）,LPS or combination of LPS and DAPT activation,respectively.Results After LPS activation of HepG2 cells,the mRNA level of Notch 1 was 2.25 times（P<0.001）,Jag 1 was 2.47 times（P<0.001）,NOTCH 3 was 0.0700 times （P>0.05）,Jag 2 was 0.420 times （P>0.05）,and Dll 4 was 0.947 times （P<0.01） increased,while NOTCH 2 was 0.857 times（P<0.01）,NOTCH 4 was 0.283 times（P>0.05）,Dll 1 was 0.750 times（P<0.01）,and Dll 3 was 0.393 times（P>0.05） decreased;the expression of NICD and NF-κB proteins in LPS-intervened cells increased obviously,while those in DAPT-intervened cells decreased greatly as compared to those in the control. Conclusion Our findings reveals that the interaction might be going on between Notch and TLR4-NF-κB signaling pathways in HepG2 cells stimulated by LPS. The inhibition of Notch signaling pathway could significantly alleviate the inflammatory response caused by LPS-TLR4.

Objective The aim of this study was to observe the efficacy of combination of ursodeoxycholic acid (UDCA) and prednisone and azathioprine in the treatment of patients with autoimmune hepatitis (AIH).Methods 120 AIH patients were recruited in the Department of Gastroenterology in our hospital between February 2017 and December 2019, and were randomly divided into control and observation groups with 60 cases in each group. The patients in the control received prednisone and azathioprine, while those in the observation group received UDCA at base of prednisone and azathioprine therapy. The regimen lasted for 21 months. Serum complement 3 (C3), C4, as well as immunoglobulin were detected.Results At the end of the treatment, serum alanine aminotransferase level in the observation group was (55.2±6.9)U/L, significantly lower than 【(91.2±12.8)U/L, P<0.05】, serum aspartate aminotransferase level was (59.7±7.5)U/L, significantly lower than 【(101.5±13.5)U/L, P<0.05】, serum alkaline phosphatase level was (122.4±15.7)U/L, much lower than 【(138.9±15.2)U/L, P<0.05】, and serum glutamyl transpeptidase level was (120.7±10.1)U/L, significantly lower than 【(161.5±20.7)U/L, P<0.05】 in the control; serum C3 level in the observation was (0.6±0.1)g/L, significantly lower than 【(0.8±0.2)g/L,P＜0.05】, and serum C4 level was (0.1±0.1)g/L, significantly lower than 【(0.2±0.1)g/L, P＜0.05】 in the control; serum IgG level in the observation group was (12.5±2.0)g/L, significantly lower than 【(20.4±2.7)g/L, P＜0.05】, and serum IgM level was (2.7±0.9)g/L, significantly lower than 【(3.4±1.1)g/L, P＜0.05】 in the control.Conclusion The administration of ursodeoxycholic acid at base of prednisolone and azathioprine combination in the treatment of patients with AIH could effectively reduce serum C3 and C4 levels, improve immune functions and alleviate liver injury, which needs further investigation.

Objective To observe the efficacy of entecavir combined with silybin meglumine amine in treatment of patients with chronic hepatitis B （CHB） and non-alcoholic fatty liver disease （NAFLD）. Methods 80 patients with CHB and NAFLD in our hospital were enrolled between January 2015 and January 2016 in this study. Patients were randomly divided into control group and observation group with 40 cases in each group. The patients in control group was treated with entecavir alone and in observation group was given entecavir combined with silybin meglumine amine. The regimen continued in both groups,and we assessed the efficacy at the end of six month treatment. Results At the end of six month treatment,serum alanine aminotransferase and aspartate amonotransferase levels in observation group were significantly lower than those in the control group[（64.3±27.9） U/L vs. （83.7±26.0） U/L,and （42.0±24.5） U/L vs. （57.6±26.6） U/L,respectively,P<0.05 for both];serum levels of PCⅢ,Ⅳ-C,LN and HA in observation group were lower than those in the control group [（106.0±54.5） ng/L vs. （147.6±76.6） ng/L,（69.23±21.24） ng/L vs. （86.74±21.30） ng/L,（119.2±61.2） ng/L vs. （212.7±100.3） ng/L,and （119.2±71.2） ng/L vs. （205.7±91.3） ng/L,respectively,P<0.05 for all];there were no differences as respect to serum HBV DNA and HBsAg levels between the two groups [（2.3±0.9） Ig IU /ml vs. （2.7±1.0） Ig IU /ml,and （4458.0±945.5） S/CO vs. （4744.0±1256.5） S/CO,respectively,P<0.05 for both]. Conclusion The combination of entecavir and silybin meglumine amine is effective in improving liver enzymes and serum indexs of hepatic fibrosis in patients with CHB and NAFLD,but we don’t find any benefit on serum HBsAg eradication by this regimen.

Objective To evaluate the diagnostic value of FibroTouch^® by fat attenuation index（FAI） in patients with non-alcoholic fatty liver diseases（NAFLD）. Methods A total of 86 patients with NAFLD and 90 healthy persons were recruited in this study. NAFLD group was divided into mild,moderate and severe liver steatosis based on B-ultrasonography. Two independent sample t-test was used to compare body mass index （BMI）,FAI and liver stiffness were obtained by FibroTouch^® between NAFLD group and healthy control. One-way analysis of variance was used to compare above parameters among mild,moderate and severe liver steatosis. Pearson correlation was used to analyze the relationship between FAI and BMI or liver stiffness. Receiver operating characteristic（ROC） curves were plotted,and the areas under the curves（AUC） were calculated. The cut-off values were defined by maximizing the sum of sensitivity and specificity（maximum Youden index）. Results Between control group and NAFLD group,BMI were [（22.9±2.1） kg/m² and （27.8±3.4） kg/m²,P<0.001],FAI were [（215.1±16.3） db/m and （263.0±25.1） db/m,P<0.001],liver stiffness were [（5.1±1.1） Kpa and （8.8±5.7） Kpa,P<0.001];Among mild（n=43）,moderate（n=28）,severe（n=15） liver steatosis,FAI showed significant difference [（244.0±9.9） db/m,（273.8±9.7） db/m and（301.9±20.1） db/m,P<0.001];FAI showed positive correlation with BMI （r=0.741,P<0.001） and liver stiffness （r=0.442,P<0.001）;AUC of normal vs. mild,mild vs. moderate, and moderate vs. severe were（0.935,0.986,and 0.969,respectively,P<0.001）;The cut-off values for mild, moderate,and severe liver steatosis were 237 db/m（sensitivity 96.7%, specificity 86.4%）,259 db/m （se. 97.7%, sp. 92.9%）,and 286 db/m（ se. 96.4%,sp. 93.3%）,respectively. Conclusion FAI shows advantages in diagnosing NAFLD,and has a promising diagnostic potential for grading liver steatosis in patients with NAFLD.